Wells Fargo & Company Raises GE HealthCare Technologies (NASDAQ:GEHC) Price Target to $85.00

Posted by Brenda Bartman on Aug 1st, 2026

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) had its price objective hoisted by stock analysts at Wells Fargo & Company from $75.00 to $85.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 24.96% from the stock’s current price.

Other equities analysts have also issued research reports about the company. Hovde Group began coverage on GE HealthCare Technologies in a report on Friday, July 17th. They set a “market perform” rating and a $14.00 price objective on the stock. Weiss Ratings downgraded GE HealthCare Technologies from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Stifel Nicolaus set a $80.00 target price on GE HealthCare Technologies in a research report on Wednesday, April 29th. Citigroup raised their price target on GE HealthCare Technologies from $69.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Piper Sandler reaffirmed a “buy” rating on shares of GE HealthCare Technologies in a research report on Wednesday. Ten equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GE HealthCare Technologies presently has an average rating of “Hold” and a consensus price target of $77.73.

Get Our Latest Stock Report on GE HealthCare Technologies

GE HealthCare Technologies Stock Down 2.7%

Shares of NASDAQ:GEHC opened at $68.02 on Thursday. The firm has a 50 day simple moving average of $64.02 and a 200-day simple moving average of $70.55. GE HealthCare Technologies has a twelve month low of $58.75 and a twelve month high of $89.77. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $30.94 billion, a PE ratio of 15.60, a P/E/G ratio of 1.90 and a beta of 0.72.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.26 billion. During the same period last year, the firm posted $1.06 EPS. The company’s revenue was up 5.8% on a year-over-year basis. On average, equities analysts predict that GE HealthCare Technologies will post 4.89 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Kevin Lobo bought 10,000 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were acquired at an average price of $64.18 per share, with a total value of $641,800.00. Following the completion of the acquisition, the director owned 14,363 shares in the company, valued at approximately $921,817.34. This trade represents a 229.20% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rodney F. Hochman purchased 1,618 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were bought at an average price of $62.03 per share, with a total value of $100,364.54. Following the purchase, the director directly owned 1,618 shares of the company’s stock, valued at approximately $100,364.54. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 12,618 shares of company stock valued at $805,175 over the last quarter. 0.36% of the stock is currently owned by insiders.

Hedge Funds Weigh In On GE HealthCare Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Auto Owners Insurance Co raised its position in GE HealthCare Technologies by 9,525.4% during the 4th quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after buying an additional 33,629,559 shares during the last quarter. Norges Bank acquired a new stake in shares of GE HealthCare Technologies in the 4th quarter worth $596,024,000. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of GE HealthCare Technologies in the fourth quarter valued at about $533,655,000. Cynosure Group LLC increased its stake in shares of GE HealthCare Technologies by 21,045.4% during the fourth quarter. Cynosure Group LLC now owns 4,365,462 shares of the company’s stock worth $358,055,000 after acquiring an additional 4,344,817 shares during the period. Finally, Boston Partners acquired a new position in shares of GE HealthCare Technologies during the third quarter worth about $287,627,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

GE HealthCare Technologies News Summary

Here are the key news stories impacting GE HealthCare Technologies this week:

Positive Sentiment: Better-than-expected earnings and raised guidance: GE HealthCare reported adjusted earnings of $1.13 per share, exceeding the $1.04 consensus estimate, while revenue of $5.30 billion also topped expectations. Revenue increased 5.8% year over year, and management raised its full-year EPS outlook. GE HealthCare Q2 2026 Earnings Call Summary
Positive Sentiment: Record backlog and solid demand: Strong orders growth and a record backlog support expectations for future revenue growth and helped reinforce the bullish case for GEHC. Analysts highlighted the backlog as evidence of durable demand for the company’s medical technology and imaging products. GE HealthCare Q2 Earnings Call Highlights
Positive Sentiment: Analyst support increased: Wells Fargo raised its price target from $75 to $85 and maintained an “overweight” rating. BTIG Research also forecast substantial appreciation, providing additional support for the shares. Wells Fargo Raises GE HealthCare Price Target
Neutral Sentiment: Execution remains a key issue: Some analysis described demand as strong but execution as weaker, suggesting investors will watch margins, delivery performance and the company’s ability to convert its backlog into sustained earnings growth. GE HealthCare Strong Demand, Weak Execution
Negative Sentiment: Shareholder investigations create legal uncertainty: Multiple law firms announced or continued investigations into possible securities-law violations and solicited investors who lost money. These announcements do not establish wrongdoing, but they may weigh on sentiment and raise potential litigation concerns. GEHC Securities Fraud Investigation

About GE HealthCare Technologies

(Get Free Report)

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.